Search research articles
Contact Us
Filters
Showing results (21-30 of 57) with videos related to
Page
of 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Cancer Chemotherapy and Pharmacology
|
February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Anthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2018
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Diwakar Davar, Hong Wang, Joe-Marc Chauvin, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 57) with videos related to
Sort By:
Page
of 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Cancer Chemotherapy and Pharmacology
|
February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Anthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
Nature Medicine
|
June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2018
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Diwakar Davar, Hong Wang, Joe-Marc Chauvin, et al.
Page
of 6